Shaker Investments LLC OH Cuts Stock Position in Medpace Holdings, Inc. (NASDAQ:MEDP)

Shaker Investments LLC OH cut its holdings in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 4.6% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 9,763 shares of the company’s stock after selling 472 shares during the period. Medpace comprises about 1.4% of Shaker Investments LLC OH’s portfolio, making the stock its 25th biggest position. Shaker Investments LLC OH’s holdings in Medpace were worth $3,259,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also made changes to their positions in the company. Rise Advisors LLC acquired a new position in shares of Medpace during the first quarter worth about $27,000. Mather Group LLC. acquired a new position in shares of Medpace during the first quarter worth about $28,000. Fidelis Capital Partners LLC acquired a new position in shares of Medpace during the first quarter worth about $31,000. J.Safra Asset Management Corp grew its position in shares of Medpace by 87.0% during the first quarter. J.Safra Asset Management Corp now owns 101 shares of the company’s stock worth $41,000 after buying an additional 47 shares in the last quarter. Finally, DT Investment Partners LLC acquired a new position in shares of Medpace during the second quarter worth about $41,000. 77.98% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of equities analysts have recently commented on the company. Jefferies Financial Group downgraded Medpace from a “buy” rating to a “hold” rating and lowered their price objective for the stock from $415.00 to $345.00 in a research report on Wednesday, September 25th. Truist Financial began coverage on Medpace in a report on Thursday, August 1st. They issued a “hold” rating and a $415.00 price target for the company. William Blair reaffirmed an “outperform” rating on shares of Medpace in a report on Wednesday, September 11th. Robert W. Baird lowered their price target on Medpace from $430.00 to $413.00 and set an “outperform” rating for the company in a report on Friday, September 20th. Finally, Deutsche Bank Aktiengesellschaft lowered their price target on Medpace from $395.00 to $336.00 and set a “hold” rating for the company in a report on Wednesday, July 24th. Five analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $395.00.

Medpace Trading Up 0.9 %

MEDP stock opened at $347.91 on Friday. The company has a market capitalization of $10.78 billion, a P/E ratio of 35.46, a PEG ratio of 1.77 and a beta of 1.35. Medpace Holdings, Inc. has a twelve month low of $227.21 and a twelve month high of $459.77. The business has a 50 day simple moving average of $359.26 and a 200-day simple moving average of $385.18.

Medpace (NASDAQ:MEDP) last posted its quarterly earnings data on Monday, July 22nd. The company reported $2.75 earnings per share for the quarter, beating the consensus estimate of $2.54 by $0.21. The business had revenue of $528.10 million during the quarter, compared to the consensus estimate of $528.41 million. Medpace had a return on equity of 55.14% and a net margin of 16.74%. The company’s revenue was up 14.6% compared to the same quarter last year. During the same period in the prior year, the company earned $1.93 earnings per share. Research analysts predict that Medpace Holdings, Inc. will post 11.64 EPS for the current fiscal year.

Medpace Company Profile

Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.